A steady stream of advances in allogeneic hematopoietic stem-celltransplantation has not only improved the clinical outcome ina variety of malignant and nonmalignant diseases but also widenedthe indications for such transplants. One important advanceis the use of sources of hematopoietic stem cells other thanbone marrow from HLA-identical siblings, which is a resourceavailable to only about 30 percent of potential recipients.
By searching international databases, which contain more than9 million potential volunteer stem-cell donors,1 a matched unrelateddonor can be found for an additional 50 to 80 percent of patients,depending on ethnic group. In . . . [Full Text of this Article]
Source Information
From the Hematology Department, Hospital Universitario La Fe, 46009 Valencia, Spain.
This article has been cited by other articles:
Atsuta, Y., Suzuki, R., Nagamura-Inoue, T., Taniguchi, S., Takahashi, S., Kai, S., Sakamaki, H., Kouzai, Y., Kasai, M., Fukuda, T., Azuma, H., Takanashi, M., Okamoto, S., Tsuchida, M., Kawa, K., Morishima, Y., Kodera, Y., Kato, S., for the Japan Marrow Donor Program and the Japan C,
(2009). Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood
113: 1631-1638
[Abstract][Full Text]